GILD

NASDAQ · Biotechnology

Gilead Sciences Inc

S&P 500 Nasdaq 100 Large-Cap Stocks Blue Chip Stocks Biotech Stocks Healthcare Stocks Best Dividend Stocks

$152.50

+3.13 (+2.10%)

As of Feb 12, 6:31 PM ET ·

Analyst Consensus

Strong Buy

Analysts

Very High

Coverage

Buy 30 81%

Hold 7 19%

Sell 0 0%

Price Target

Analyst Price Target +137.8% upside

Low Target $213.16

Average Target $362.68

High Target $477.67

Current Price $152.50

Current
$152.50

Target
$362.68

$213.16 $362.68 avg $477.67

Scenario Analysis

Bear Case

$213.16

39.8%

Low target

Base Case

$362.68

+137.8%

Avg target

Bull Case

$477.67

+213.2%

High target

Risk/Reward

5.4x

Highly favorable

Price in Context

52-Week High

$153.13

-0.4% from high

52-Week Low

$93.37

+63.3% from low

50-Day SMA

$127.52

+19.6% vs SMA

200-Day SMA

$116.77

+30.6% vs SMA

RSI (14)

93.1

Overbought

Target vs 52W High

$362.68

+136.8% vs high

Peer Consensus — Biotechnology

Stock	Consensus	Analysts	Buy %	Target	Upside
ABBV Abbvie Inc	Buy	37	68%	$257.58	+15.3%
AMGN Amgen Inc	Hold	41	54%	$190.87	-50.3%
GILD Gilead Sciences Inc	Strong Buy	37	81%	$362.68	+137.8%
VRTX Vertex Pharmaceuticals Inc	Strong Buy	39	77%	$438.34	-8.3%
REGN Regeneron Pharmaceuticals	Strong Buy	36	75%	$76.80	-90.2%
ALNY Alnylam Pharmaceuticals Inc	Strong Buy	36	75%	$102.31	-68.8%
INSM Insmed Inc	Strong Buy	27	93%	$143.40	-4.3%
BIIB Biogen Inc	Hold	42	48%	$91.45	-54.5%